Endocrine Abstracts

Background: CCH and serum hypercalcitoninemia (iperCT) can be found in benign thyroid diseases such as thyroiditis and in some cases of papillary (PTC) or follicular (FTC) thyroid microcarcinomas. The question of whether the association with these latter is related to the malignancy of the nodule is still unclear.Aim of the study: To evaluate the difference in the CCH prevalence, at histology, in a series of benign (BTN) and malignant (PTC/FTC) thyroid n...

Genetic intratumor heterogeneity has been recently demonstrated in some solid human cancers and a few years ago RET mutated and not mutated cells were described in medullary thyroid carcinoma (MTC). Nobody reported the presence of two different RET mutations.Aim of our study was to investigate the RET somatic mutation profile in primary MTC (pMTC) and in the corresponding metastatic tissues (mets).We studied pMTC and mets of 22 MTC...

Several studies have identified a relationship between oncogene activation and dedifferentiation of PTC. Mutations of RAS, RET/PTC and BRAF modulate the expression of thyroid genes. An impaired NIS expression has been demonstrated in PTCs harboring the BRAFV600E mutation.Aim of this study was to analyze BRAF and RET/PTC1-3 alterations and their influence on the expression of thyroid differentiation genes. Seventy-one PTC samples were studied. Quantitative analysis o...

18FDG-PET is based on the capability of tumor cells to take up glucose. An increment in expression of the glucose transporter 1 (GLUT1) has been observed in thyroid tumors with poor prognosis but very few data are available about the expression of other glucose transporters in thyroid. Here, we study the expression and function of GLUT isoforms 1, 2, 3, 4, 6, 8, 10, 12 in human thyroid carcinoma cell lines ARO and FRO (anaplastic carcinoma), NPA (poorly-differentiated papillar...

Germline point mutations of the RET proto-oncogene are causative of hereditary MTC. Somatic mutations are described in 40% of sporadic MTCs. Although a relationship between somatic mutations and bad prognosis has been described, data are controversial.No date on the prognostic value of RET polymorphisms are available.Aim of the work was to verify if the presence of a somatic RET mutation and or a polymorphisms can influence the prognosis of MTC. This stu...

In a previous study we demonstrated that retinoic acid (RA) decreased the growth only of thyroid carcinoma cell lines expressing RA receptor β (RAR β) and that decitabine (5-Aza-CdR) re-induced RARβ expression. The aim of this study was to analyze the effects induced by the combined treatment with RA and 5-Aza-CdR in the same thyroid cancer cell lines.We studied the effect of 5-Aza-CdR 800 nM and RA 1 μM on the expression of thyroid s...

Objective: Currently, data about the molecular profile of multifocal papillary thyroid cancer (PTC) are still controversial. The aim of this study was to fully characterize by NGS the molecular profile of different histological variants in patients affected by multifocal PTCs.Methods: for this purpose, 12 multifocal PTC patients have been studied based to the following inclusion criteria: 1) a minimum of two tumors foci per patient with at least two diff...

Lenvatinib is a tyrosine kinase inhibitor (TKI), approved for the management of locally recurrent or metastatic, progressive, radioactive iodine–refractory differentiated thyroid cancer (DTC). A side effect of this drug is the tracheoesophageal fistula, described in 14.7% of patients. When this side effect is present, the interruption/withdrawn of the TKI is required and in this case no valid therapeutic options are described. We present the case of a 63-year-old woman pa...

Objectives: PET/CT scan with 18F-fluoro-dihydroxyphenylalanine (18F-DOPA) is an emerging useful tool in medullary thyroid cancer (MTC) patients. The question whether 18F-DOPA-PET/CT could be useful in MTC patients with biochemical incomplete response (BiR) is to clarify.Methods: Fifty-three MTC patients with BiR performed 18F-DOPA-PET/CT scan between May 2021 and December 2022 after having performed total body ...

Introduction: Medullary thyroid carcinoma (MTC) is a rare neoplasm that occurs sporadically in 75% (sMTC) and hereditarily in 25% (fMTC) of cases caused by germinal mutations of the RET gene as an autosomal dominant trait. fMTC occurs in the setting of three syndromes: fMTC alone without any other clinical manifestations; and multiple endocrine neoplasia type 2A (MEN2A) and 2B (MEN2B) syndromes. In fMTC, cases are distinguished into index cases (1st clinically detecte...